MiMedx Group, Inc (MDXG): Price and Financial Metrics


MiMedx Group, Inc (MDXG): $6.26

0.10 (+1.62%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MDXG to Watchlist
Sign Up

Industry: Biotech


Ranked

of 505

in industry

MDXG POWR Grades


  • Growth is the dimension where MDXG ranks best; there it ranks ahead of 97.09% of US stocks.
  • The strongest trend for MDXG is in Sentiment, which has been heading up over the past 48 weeks.
  • MDXG's current lowest rank is in the Stability metric (where it is better than 38.95% of US stocks).

MDXG Stock Summary

  • Mimedx Group Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 0.52% of US listed stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -321.44 for Mimedx Group Inc; that's greater than it is for just 0.09% of US stocks.
  • Over the past twelve months, MDXG has reported earnings growth of 672%, putting it ahead of 96.56% of US stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Mimedx Group Inc are KFS, CDK, WYNN, IMTE, and RPD.
  • Visit MDXG's SEC page to see the company's official filings. To visit the company's web site, go to www.mimedx.com.

MDXG Valuation Summary

  • MDXG's EV/EBIT ratio is -20.6; this is 170.31% lower than that of the median Healthcare stock.
  • Over the past 165 months, MDXG's EV/EBIT ratio has gone up 906.4.
  • MDXG's EV/EBIT ratio has moved up 906.4 over the prior 165 months.

Below are key valuation metrics over time for MDXG.

Stock Date P/S P/B P/E EV/EBIT
MDXG 2021-08-31 6.3 -231.5 -19.9 -20.6
MDXG 2021-08-30 6.3 -228.7 -19.6 -20.4
MDXG 2021-08-27 6.0 -221.2 -19.0 -19.7
MDXG 2021-08-26 6.0 -217.9 -18.7 -19.4
MDXG 2021-08-25 6.0 -217.7 -18.7 -19.4
MDXG 2021-08-24 6.0 -219.3 -18.8 -19.5

MDXG Growth Metrics

  • Its 2 year net income to common stockholders growth rate is now at -164.5%.
  • The 4 year price growth rate now stands at -22.86%.
  • Its 2 year revenue growth rate is now at 47.29%.
MDXG's revenue has moved up $85,949,148 over the prior 70 months.

The table below shows MDXG's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 260.983 -19.965 -83.167
2021-03-31 246.465 -24.661 -88.357
2020-12-31 248.234 -30.263 -83.328
2020-09-30 256.086 -43.118 -72.745
2020-06-30 280.646 -41.66 -8.384
2020-03-31 294.436 -36.433 -17.128

MDXG's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MDXG has a Quality Grade of C, ranking ahead of 64.29% of graded US stocks.
  • MDXG's asset turnover comes in at 1.316 -- ranking 9th of 183 Medical Equipment stocks.
  • 500 - Internal server error

The table below shows MDXG's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 1.316 0.833 -1.110
2021-03-31 1.302 0.842 -1.153
2020-12-31 1.369 0.842 -1.200
2017-09-30 1.597 0.881 0.532
2017-06-30 1.485 0.878 0.420
2017-03-31 1.427 0.874 0.360

MDXG Price Target

For more insight on analysts targets of MDXG, see our MDXG price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $16.17 Average Broker Recommendation 1.5 (Moderate Buy)

MDXG Stock Price Chart Interactive Chart >

Price chart for MDXG

MDXG Price/Volume Stats

Current price $6.26 52-week high $15.99
Prev. close $6.16 52-week low $5.30
Day low $6.12 Volume 1,357,100
Day high $6.43 Avg. volume 822,977
50-day MA $11.66 Dividend yield N/A
200-day MA $10.51 Market Cap 700.81M

MiMedx Group, Inc (MDXG) Company Bio


MiMedx Group developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. The company was founded in 2008 and is based in Marietta, Georgia.


MDXG Latest News Stream


Event/Time News Detail
Loading, please wait...

MDXG Latest Social Stream


Loading social stream, please wait...

View Full MDXG Social Stream

Latest MDXG News From Around the Web

Below are the latest news stories about Mimedx Group Inc that investors may wish to consider to help them evaluate MDXG as an investment opportunity.

MDXG: Unexpected Results Call for a Revision

By John Vandermosten, CFA NASDAQ:MDXG READ THE FULL MDXG RESEARCH REPORT Topline Results from Phase IIb KOA and Phase III PF On September 13, 2021, MiMedx Group, Inc. (NASDAQ:MDXG) reported results from its Phase IIb Knee Osteoarthritis (KOA) study and topline results from its Phase III Plantar Fasciitis (PF) study. Six-month efficacy data from the Phase IIb KOA study interim results did not meet

Yahoo | September 20, 2021

Why MiMedx Shares Are Diving Today

MiMedx Group Inc (NASDAQ: MDXG ) is trading significantly lower Monday after the company announced top-line results from two late-stage musculoskeletal clinical trials. Top-line results from an interim analysis of the six-month efficacy data for the Phase 2B clinical trial for Knee Osteoarthritis (KOA) did not meet primary endpoints, but revealed varied efficacy signals, prompting the company to plan for confirmatory Full story available on Benzinga.com

Benzinga | September 13, 2021

Mimedx Stock Plunges After Disappointing Data From Musculoskeletal Trials

MiMedx Group Inc (NASDAQ: MDXG ) stock dropped after announcing top-line results from two musculoskeletal trials of micronized dehydrated Human Amnion Chorion Membrane (mdHACM). Top-line results from an interim analysis of the six-month efficacy data for the Phase 2B trial for Knee Osteoarthritis (KOA) Full story available on Benzinga.com

Benzinga | September 13, 2021

Why Shares of MiMedx Are Collapsing Today

The company released data for two drug programs and missed its goals on both.

The Motley Fool | September 13, 2021

MIMEDX Reports Top-line Data from Two Late-Stage Musculoskeletal Trials with Proprietary Amniotic Tissue Technology

Phase 2B Knee Osteoarthritis (KOA) Study Top-line Interim Results Demonstrate Varied Efficacy Signals between Patient Cohorts

Intrado Digital Media | September 13, 2021

Read More 'MDXG' Stories Here

MDXG Price Returns

1-mo -55.22%
3-mo -44.40%
6-mo -36.12%
1-year -2.80%
3-year 4.33%
5-year -29.90%
YTD -31.06%
2020 19.79%
2019 323.46%
2018 -85.80%
2017 42.33%
2016 -5.44%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.4926 seconds.